Skip to main content
Log in

Comment on: “Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson’s Disease: A Systematic Review”

  • Letter to the Editor
  • Published:
CNS Drugs Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 19 August 2016

The Original Article was published on 30 April 2016

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wirdefeldt K, Odin P, Nyholm D. Levodopa-carbidopa intestinal gel in patients with Parkinson’s disease: a systematic review. CNS Drugs. 2016;30(5):381–404.

    Article  CAS  PubMed  Google Scholar 

  2. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–9.

    Article  CAS  PubMed  Google Scholar 

  3. Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson’s disease patients. J Parkinsons Dis. 2015;5(1):165–74.

    CAS  PubMed  Google Scholar 

  4. Aarsland D, Andersen K, Larsen JP, Lolk A. Prevalence and characteristics of dementia in parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387–92.

    Article  PubMed  Google Scholar 

  5. DANMODIS, Danish Movement Disorder Society; SWEMODIS SMDS. Treatment with levodopa/carbidopa gel (Duodopa) in patients with Parkinson’s disease [Internet]. 2008. http://parkinsoninfo.parkinsonforbundet.se/wp-content/uploads/duodopakonsensus-20081.pdf. Accessed 28 July 2016.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andrew T. Lambarth.

Ethics declarations

Funding

No funding was received for this publication.

Conflicts of interest

Andrew Lambarth has no conflicts of interest associated with this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lambarth, A.T. Comment on: “Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson’s Disease: A Systematic Review”. CNS Drugs 30, 1007–1008 (2016). https://doi.org/10.1007/s40263-016-0378-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-016-0378-8

Keywords

Navigation